

**TOXICOLOGICAL PROFILE FOR
CHLORFENVINPHOS**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 1997

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



David Satcher, M.D., Ph.D.
Administrator
Agency for Toxic Substances and
Disease Registry

*Legislative Background

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on April 29, 1996 (61 FR 18744). For prior versions of the list of substances, see *Federal Register* notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHORS(S):

Alfred S. Dorsey, Jr., D.V.M.
ATSDR, Division of Toxicology, Atlanta, GA

Steven S. Kueberuwa, M.S.
Research Triangle Institute, Research Triangle Park, NC

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Green Border Review. Green Border review assures consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.

PEER REVIEW

A peer review panel was assembled for chlorfenvinphos. The panel consisted of the following members:

1. Dr. Frederick Oehme, Professor, Kansas State University, Manhattan, KS;
2. Dr. Casey Robinson, Professor of Pharmacology and Toxicology, University of Oklahoma, Oklahoma City, OK; and
3. Dr. Syed Naqvi, Professor of Biology, Southern University Department of Biological Sciences, Baton Rouge, LA.

These experts collectively have knowledge of chlorfenvinphos' physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

FOREWORD	v
CONTRIBUTORS	vii
PEER REVIEW	ix
LIST OF FIGURES	xv
LIST OF TABLES	xvii
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS CHLORFENVINPHOS?	1
1.2 WHAT HAPPENS TO CHLORFENVINPHOS WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO CHLORFENVINPHOS?	2
1.4 HOW CAN CHLORFENVINPHOS ENTER AND LEAVE MY BODY?	3
1.5 HOW CAN CHLORFENVINPHOS AFFECT MY HEALTH?	3
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO CHLORFENVINPHOS?	4
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	5
1.8 WHERE CAN I GET MORE INFORMATION?	6
2. HEALTH EFFECTS	7
2.1 INTRODUCTION	7
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	7
2.2.1 Inhalation Exposure	9
2.2.2 Oral Exposure	16
2.2.3 Dermal Exposure	47
2.3 TOXICOKINETICS	49
2.3.1 Absorption	50
2.3.2 Distribution	51
2.3.3 Metabolism	54
2.3.4 Elimination and Excretion	59
2.3.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ..	60
2.4 MECHANISMS OF ACTION	63
2.4.1 Pharmacokinetic Mechanisms	63
2.4.2 Mechanisms of Toxicity	66
2.4.3 Animal-to-Human Extrapolations	68
2.5 RELEVANCE TO PUBLIC HEALTH	69
2.6 BIOMARKERS OF EXPOSURE AND EFFECT	89
2.6.1 Biomarkers Used to Identify or Quantify Exposure to Chlorfenvinphos	90
2.6.2 Biomarkers Used to Characterize Effects Caused by Chlorfenvinphos	92
2.7 INTERACTIONS WITH OTHER CHEMICALS	93
2.8 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	94

2.9	METHODS FOR REDUCING TOXIC EFFECTS	96
2.9.1	Reducing Peak Absorption Following Exposure	96
2.9.2	Reducing Body Burden	97
2.9.3	Interfering with the Mechanism of Action for Toxic Effects	97
2.10	ADEQUACY OF THE DATABASE	98
2.10.1	Existing Information on Health Effects of Chlorfenvinphos	98
2.10.2	Identification of Data Needs	101
2.10.3	Ongoing Studies	114
3.	CHEMICAL AND PHYSICAL INFORMATION	115
3.1	CHEMICAL IDENTITY	115
3.2	PHYSICAL AND CHEMICAL PROPERTIES	115
4.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	119
4.1	PRODUCTION	119
4.2	IMPORT/EXPORT	119
4.3	USE	120
4.4	DISPOSAL	123
5.	POTENTIAL FOR HUMAN EXPOSURE	125
5.1	OVERVIEW	125
5.2	RELEASES TO THE ENVIRONMENT	126
5.2.1	Air	128
5.2.2	Water	128
5.2.3	Soil	129
5.3	ENVIRONMENTAL FATE	129
5.3.1	Transport and Partitioning	129
5.3.2	Transformation and Degradation	133
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	141
5.4.1	Air	141
5.4.2	Water	141
5.4.3	Sediment and Soil	142
5.4.4	Other Environmental Media	142
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	144
5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	145
5.7	ADEQUACY OF THE DATABASE	146
5.7.1	Identification of Data Needs	146
5.7.2	Ongoing Studies	150
6.	ANALYTICAL METHODS	151
6.1	BIOLOGICAL SAMPLES	151
6.2	ENVIRONMENTAL SAMPLES	153
6.3	ADEQUACY OF THE DATABASE	157
6.3.1	Identification of Data Needs	159
6.3.2	Ongoing Studies	161
7.	REGULATIONS AND ADVISORIES	163
8.	REFERENCES	165
9.	GLOSSARY	181

APPENDICES

A. MINIMAL RISK LEVEL WORKSHEETS A-1

B. USER'S GUIDE B-1

C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS C-1

LIST OF FIGURES

2-1	Levels of Significant Exposure to Chlorfenvinphos - Inhalation	11
2-2	Levels of Significant Exposure to Chlorfenvinphos - Oral	28
2-3	Proposed Mammalian Metabolic Pathway for Chlorfenvinphos	46
2-4	Conceptual Representation of the Physiologically-based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	62
2-5	Existing Information on Health Effects of Chlorfenvinphos	100
5-1	Frequency of NPL Sites With Chlorfenvinphos Contamination	127
5-2	Hydrolysis Pathways for Chlorfenvinphos in Water	135
5-3	Environmental Degradation Pathways for Chlorfenvinphos in Soil	137
5-4	Environmental Transformation Pathways for Chlorfenvinphos in Plants	140

LIST OF TABLES

2-1	Levels of Significant Exposure to Chlorfenvinphos - Inhalation	10
2-2	Levels of Significant Exposure to Chlorfenvinphos - Oral	18
2-3	Genotoxicity of Chlorfenvinphos <i>In Vivo</i>	87
2-4	Genotoxicity of Chlorfenvinphos <i>In Vitro</i>	88
3-1	Chemical Identity of Chlorfenvinphos	116
3-2	Physical and Chemical Properties of Chlorfenvinphos	117
4-1	Previously Registered Uses of Chlorfenvinphos	121
4-2	Chlorfenvinphos Product Registrations and Dates of Cancellation in the United States	124
6-1	Analytical Methods for Determining Chlorfenvinphos in Biological Samples	152
6-2	Analytical Methods for Determining Chlorfenvinphos in Environmental Samples	154
6-3	Analytical Methods for Determining Environmental Degradation Products of Chlorfenvinphos	158
6-4	Analytical Methods for Determining Biomarkers for Chlorfenvinphos	160
7-1	Regulations and Guidelines Applicable to Chlorfenvinphos	164

